Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Sebastian Schneeweiss, Sc.D., M.D.

Co-Author

This page shows the publications co-authored by Sebastian Schneeweiss and Rishi Desai.
Connection Strength

5.901
  1. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. Ann Hematol. 2020 Nov; 99(11):2497-2505.
    View in: PubMed
    Score: 0.953
  2. Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. JAMA Netw Open. 2020 01 03; 3(1):e1918962.
    View in: PubMed
    Score: 0.911
  3. Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. Circ Cardiovasc Qual Outcomes. 2018 12; 11(12):e004700.
    View in: PubMed
    Score: 0.844
  4. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 03 09; 143(10):1002-1013.
    View in: PubMed
    Score: 0.243
  5. Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Alzheimers Dement (N Y). 2020; 6(1):e12095.
    View in: PubMed
    Score: 0.242
  6. Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees. Eur J Haematol. 2021 Feb; 106(2):273-280.
    View in: PubMed
    Score: 0.242
  7. Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clin Epidemiol. 2020; 12:607-616.
    View in: PubMed
    Score: 0.235
  8. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. Clin Pharmacol Ther. 2020 Oct; 108(4):874-884.
    View in: PubMed
    Score: 0.234
  9. Statin Lipophilicity and the Risk of Incident Heart Failure. Cardiology. 2020; 145(6):375-383.
    View in: PubMed
    Score: 0.232
  10. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Intern Med. 2019 06 01; 179(6):741-749.
    View in: PubMed
    Score: 0.219
  11. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2019 10; 49(2):222-228.
    View in: PubMed
    Score: 0.215
  12. Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clin Pharmacol Ther. 2019 06; 105(6):1513-1521.
    View in: PubMed
    Score: 0.215
  13. Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. Pharmacoepidemiol Drug Saf. 2018 Dec; 27(12):1361-1370.
    View in: PubMed
    Score: 0.210
  14. Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. Am J Kidney Dis. 2018 08; 72(2):178-187.
    View in: PubMed
    Score: 0.204
  15. Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. J Comp Eff Res. 2017 Oct; 6(7):613-625.
    View in: PubMed
    Score: 0.195
  16. Tumor Necrosis Factor-a Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology. 2016 May; 27(3):414-22.
    View in: PubMed
    Score: 0.176
  17. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2020 Dec 30.
    View in: PubMed
    Score: 0.061
  18. Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. Epidemiology. 2020 01; 31(1):82-89.
    View in: PubMed
    Score: 0.057
  19. Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Wash DC). 2019 Jul 15; 7(1):27.
    View in: PubMed
    Score: 0.055
  20. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 04; 78(4):456-464.
    View in: PubMed
    Score: 0.053
  21. Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. Clin Pharmacol Ther. 2019 05; 105(5):1156-1163.
    View in: PubMed
    Score: 0.052
  22. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018 07 12; 9(1):2691.
    View in: PubMed
    Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.